Methods and materials for treating diabetes or liver steatosis

ABSTRACT

This document provides methods and materials for treating diabetes and/or liver steatosis. For example, methods for using compositions containing a potato polysaccharide preparation to reduce one or more symptoms of diabetes or liver steatosis are provided.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.15/023,069, filed Mar. 18, 2016, which is 371 National Stage Applicationof International Application No. PCT/US2014/053443, filed Aug. 29, 2014,which claims priority to, and the benefit of, U.S. ProvisionalApplication No. 61/879,992, filed Sep. 19, 2013, all of which areincorporated by reference herein in their entirety.

BACKGROUND 1. Technical Field

This document relates to methods and materials for treating diabetesand/or liver steatosis. For example, this document relates to usingcompositions containing a potato polysaccharide preparation to reduceone or more symptoms of diabetes or liver steatosis. In some cases, thisdocument relates to using compositions containing a potatopolysaccharide preparation to reduce triglyceride levels, to reduceserum glucose levels, to reduce water consumption, to reduce urineproduction, to reduce kidney weight, to reduce liver weight, and/or toincrease abdominal fat.

2. Background Information

Potatoes are starchy, edible tubers obtained from potato plants and forman integral part of much of the world's food supply. In fact, potatoesare the fourth largest food crop in the world. The main potato speciesworldwide is Solanum tuberosum.

SUMMARY

This document provides methods and materials for treating diabetesand/or liver steatosis. For example, this document provides methods forusing compositions containing a potato polysaccharide preparation toreduce one or more symptoms of diabetes or liver steatosis. In somecases, a composition containing a potato polysaccharide preparationprovided herein can be used to reduce triglyceride levels, to reduceserum glucose levels, to reduce water consumption, to reduce urineproduction, to reduce kidney weight, to reduce liver weight, and/or toincrease abdominal fat. In some cases, a composition containing a potatopolysaccharide preparation provided herein can be used to treat fattyliver disease.

Having the ability to use a composition containing a potatopolysaccharide preparation described herein to reduce one or moresymptoms of diabetes or liver steatosis can provide clinicians andpatients with an effective treatment regime for these conditions.

This document also provides compositions (e.g., nutritional supplementcompositions) that contain a potato polysaccharide preparation. Forexample, this document provides nutritional supplement compositionscontaining a potato polysaccharide preparation, methods for obtainingpotato polysaccharide preparations, methods for making nutritionalsupplement compositions containing a potato polysaccharide preparation,and methods for increasing or decreasing expression of polypeptidesinvolved with mitochondria activity or function.

In some cases, the compositions provided herein (e.g., nutritionalsupplement compositions and potato polysaccharide preparations providedherein) can be used to increase or decrease expression of polypeptidesinvolved with mitochondria activity or function. For example, acomposition containing a potato polysaccharide preparation providedherein or a potato polysaccharide preparation provided herein can beused to increase expression of a transcription factor A, mitochondrialpolypeptide (a TFAM polypeptide), an ATP synthase, H⁺ transporting,mitochondrial F1 complex, alpha subunit 1 polypeptide (an ATP5A1polypeptide), a pyruvate dehydrogenase (lipoamide) alpha 1 polypeptide(a PDHA1 polypeptide), a pyruvate dehydrogenase (lipoamide) alpha 2polypeptide (a PDHA2 polypeptide), a thimet oligopeptidase 1 polypeptide(a THOP1 polypeptide), or a combination thereof. In some cases, acomposition containing a potato polysaccharide preparation providedherein or a potato polysaccharide preparation provided herein can beused to decrease expression of a forkhead box O1 polypeptide (a FOX01Apolypeptide), a nuclear factor of kappa light polypeptide gene enhancerin B-cells 1 polypeptide (a NFKB1 polypeptide), a pyruvate dehydrogenasekinase, isozyme 2 polypeptide (a PDK2 polypeptide), a pyruvatedehydrogenase kinase, isozyme 4 polypeptide (a PDK4 polypeptide), a3-hydroxy-3-methylglutaryl-CoA reductase polypeptide (a HMGCRpolypeptide), or a combination thereof. In some case, a compositioncontaining a potato polysaccharide preparation provided herein or apotato polysaccharide preparation provided herein can be used toincrease one or more polypeptides (e.g., one or more of a TFAMpolypeptide, an ATP5A1 polypeptide, a PDHA1 polypeptide, a PDHA2polypeptide, or a THOP1 polypeptide) and decrease one or morepolypeptides (e.g., one or more of a FOX01A polypeptide, a NFKB1polypeptide, a PDK2 polypeptide, a PDK4 polypeptide, or a HMGCRpolypeptide).

In some cases, a composition provided herein (e.g., a nutritionalsupplement composition or potato polysaccharide preparation providedherein) can be used to increase or decrease expression of polypeptidesinvolved with diabetes or liver steatosis. For example, a compositionprovided herein (e.g., a nutritional supplement composition containing apotato polysaccharide preparation provided herein or a potatopolysaccharide preparation provided herein) can be used to increaseexpression of a lipase, hormone-sensitive polypeptide (an LIPEpolypeptide) in adipocytes, to increase expression of aphosphoenolpyruvate carboxykinase 2 (mitochondrial) polypeptide (a PCK2polypeptide), to increase expression of a monoacylglycerolO-acyltransferase 1 polypeptide (an MOGAT1 polypeptide), to increaseexpression of a peroxisome proliferator-activated receptor gamma,coactivator 1 alpha polypeptide (a PPARGC1a polypeptide), to increaseexpression of a peroxisome proliferator-activated receptor gamma,coactivator 1 beta polypeptide (a PPARGC 1b polypeptide), to increaseexpression of a superoxide dismutase 2, mitochondrial polypeptide (anSOD2 polypeptide), to increase expression of a nuclear receptorsubfamily 4, group A, member 1 polypeptide (an NR4A1 polypeptide) inadipocytes, to increase expression of an acetyl-CoA acetyltransferase 2polypeptide (an ACAT2 polypeptide), to increase expression of a3-hydroxy-3-methylglutaryl-CoA reductase polypeptide (an HMGCRpolypeptide) in muscle cells, or a combination thereof. In some cases, acomposition provided herein (e.g., a nutritional supplement compositionor potato polysaccharide preparation provided herein) can be used todecrease expression of a 1-acylglycerol-3-phosphate O-acyltransferase 1polypeptide (an AGPAT1 polypeptide), to decrease expression of anoxidized low density lipoprotein (lectin-like) receptor 1 polypeptide(an OLR1 polypeptide), to decrease expression of a branched chainamino-acid transaminase 2, mitochondrial polypeptide (a BCAT2polypeptide), to decrease expression of a nuclear factor of kappa lightpolypeptide gene enhancer in B-cells 1 polypeptide (an NFKB1polypeptide), to decrease expression of a SH2B adaptor protein 1polypeptide (an SH2B1 polypeptide), to decrease expression of alipoprotein lipase polypeptide (an LPL polypeptide), to decreaseexpression of a 3-hydroxy-3-methylglutaryl-CoA reductase polypeptide (anHMGCR polypeptide) in adipocytes, to decrease expression of a lipase,hormone-sensitive polypeptide (an LIPE polypeptide) in muscle cells, todecrease expression of a nuclear receptor subfamily 4, group A, member 1polypeptide (an NR4A1 polypeptide) in muscle cells, to decreaseexpression of a phosphatase and tensin homolog polypeptide (a PTENpolypeptide), to decrease expression of a caspase 8, apoptosis-relatedcysteine peptidase polypeptide (a CASP8 polypeptide), or a combinationthereof.

In some cases, a composition provided herein (e.g., a nutritionalsupplement composition or potato polysaccharide preparation providedherein) can be used to increase one or more polypeptides (e.g., one ormore of an LIPE polypeptide (in adipocytes), a PCK2 polypeptide, anMOGAT1 polypeptide, a PPARGC1a polypeptide, a PPARGC1b polypeptide, anSOD2 polypeptide, an NR4A1 polypeptide (in adipocytes), an ACAT2polypeptide, or an HMGCR polypeptide (in muscle cells)) and decrease oneor more polypeptides (e.g., one or more of an AGPAT1 polypeptide, anOLR1 polypeptide, a BCAT2 polypeptide, an NFKB1 polypeptide, an SH2B1polypeptide, an LPL polypeptide, an HMGCR polypeptide (in adipocytes),an LIPE polypeptide (in muscle cells), an NR4A1 polypeptide (in musclecells), a PTEN polypeptide, or a CASP8 polypeptide).

In general, one aspect of this document features a method for treatingdiabetes. The method comprises, or consists essentially of, (a)identifying a mammal with diabetes, and (b) administering to the mammala composition comprising a potato polysaccharide preparation obtainedfrom raw potatoes, wherein the severity of a symptom of the diabetes isreduced. The composition can comprise the potato polysaccharidepreparation in an amount that results in between 0.05 mg and 50 mg ofthe potato polysaccharide component of the potato polysaccharidepreparation being administered to the mammal per kg of body weight ofthe mammal. The composition can comprise between 1 mg and 100 mg of thepotato polysaccharide preparation. The composition can comprise between6 mg and 20 mg of the potato polysaccharide preparation. The compositioncan comprise between 1 mg and 100 mg of the potato polysaccharidecomponent of the potato polysaccharide preparation. The composition cancomprise between 6 mg and 20 mg of the potato polysaccharide componentof the potato polysaccharide preparation. The composition can be in theform of a tablet. The composition can comprise alpha lipoic acid. Thecomposition can comprise alpha tocopherol. The potato polysaccharidepreparation can be in an amount that results in between 0.075 mg and 0.5mg of the potato polysaccharide component of the potato polysaccharidepreparation being administered to the mammal per kg of body weight ofthe mammal. At least about 80 percent of the potato polysaccharidepreparation can be potato polysaccharide. At least about 90 percent ofthe potato polysaccharide preparation can be potato polysaccharide. Atleast about 95 percent of the potato polysaccharide preparation can bepotato polysaccharide. The mammal can be a human.

In another aspect, this document features a method for treating a fattyliver disease. The method comprises, or consists essentially of, (a)identifying a mammal with a fatty liver disease, and (b) administeringto the mammal a composition comprising a potato polysaccharidepreparation obtained from raw potatoes, wherein the severity of asymptom of the fatty liver disease is reduced. The composition cancomprise the potato polysaccharide preparation in an amount that resultsin between 0.05 mg and 50 mg of the potato polysaccharide component ofthe potato polysaccharide preparation being administered to the mammalper kg of body weight of the mammal. The composition can comprisebetween 1 mg and 100 mg of the potato polysaccharide preparation. Thecomposition can comprise between 6 mg and 20 mg of the potatopolysaccharide preparation. The composition can comprise between 1 mgand 100 mg of the potato polysaccharide component of the potatopolysaccharide preparation. The composition can comprise between 6 mgand 20 mg of the potato polysaccharide component of the potatopolysaccharide preparation. The composition can be in the form of atablet. The composition can comprise alpha lipoic acid. The compositioncan comprise alpha tocopherol. The potato polysaccharide preparation canbe in an amount that results in between 0.075 mg and 0.5 mg of thepotato polysaccharide component of the potato polysaccharide preparationbeing administered to the mammal per kg of body weight of the mammal. Atleast about 80 percent of the potato polysaccharide preparation can bepotato polysaccharide. At least about 90 percent of the potatopolysaccharide preparation can be potato polysaccharide. At least about95 percent of the potato polysaccharide preparation can be potatopolysaccharide. The mammal can be a human.

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention pertains. Although methods and materialssimilar or equivalent to those described herein can be used in thepractice or testing of the present invention, suitable methods andmaterials are described below. All publications, patent applications,patents, and other references mentioned herein are incorporated byreference in their entirety. In case of conflict, the presentspecification, including definitions, will control. In addition, thematerials, methods, and examples are illustrative only and not intendedto be limiting.

Other features and advantages of the invention will be apparent from thefollowing detailed description, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 is an HPLC chromatogram of a 10% ACN extract of raw potato(Russet Burbank).

FIG. 2 is an HPLC chromatogram of collected and re-purified 3.5 minutepeak material from a 10% ACN extract of raw potato shown in FIG. 1.

FIG. 3 is a representative real time PCR amplification plot for TFAMexpression.

FIG. 4 is an LC/MS trace of 3.5 minute HPLC peak material.

FIG. 5 is a full NMR spectrum of 3.5 minute HPLC peak material.

FIG. 6 is an expanded NMR spectrum of 3.5 minute HPLC peak material.

FIG. 7 is a total ion chromatogram of derivatized carbohydrate fragmentsof 3.5 minute HPLC peak material obtained from raw potato RussetBurbank).

FIG. 8 is a fragmentation pattern of diacetamide. The peak fragmentationpattern is in the top panel, the compound library fragmentation match isin the bottom panel, and an overlay of the two is in the center panel.

FIG. 9 is a fragmentation pattern of 3-acetoxy pyridine. The peakfragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 10 is a fragmentation pattern of 3,4-furan dimethanol, diacetate.The peak fragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 11 is a fragmentation pattern of 1,2,3-propanetriol diacetate. Thepeak fragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 12 is a fragmentation pattern of imidazole, 2-acetamino-5-methyl.The peak fragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 13 is a fragmentation pattern of6,7-dihydro-5H-pyrrol[2,1,c][1,2,4] triazole-3-carboxylic acid. The peakfragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 14 is a fragmentation pattern of acetic acid,1-(2-methyltetrazol-5-yl) ethenyl ester. The peak fragmentation patternis in the top panel, the compound library fragmentation match is in thebottom panel, and an overlay of the two is in the center panel.

FIG. 15 is a fragmentation pattern of 1,2,3,4-butanetriol, tetraacetate(isomer 1). The peak fragmentation pattern is in the top panel, thecompound library fragmentation match is in the bottom panel, and anoverlay of the two is in the center panel.

FIG. 16 is a fragmentation pattern of 1,2,3,4-butanetriol, tetraacetate(isomer 2). The peak fragmentation pattern is in the top panel, thecompound library fragmentation match is in the bottom panel, and anoverlay of the two is in the center panel.

FIG. 17 is a fragmentation pattern of pentaerythritol tetraacetate. Thepeak fragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 18 is a fragmentation pattern of 1,2,3,4,5-penta-o-acetyl-D-xylitol(isomer 1). The peak fragmentation pattern is in the top panel, thecompound library fragmentation match is in the bottom panel, and anoverlay of the two is in the center panel.

FIG. 19 is a fragmentation pattern of 1,2,3,4,5-penta-o-acetyl-D-xylitol(isomer 2). The peak fragmentation pattern is in the top panel, thecompound library fragmentation match is in the bottom panel, and anoverlay of the two is in the center panel.

FIG. 20 is a fragmentation pattern of 3,5-diacetoxy benzyl alcohol. Thepeak fragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 21 is a fragmentation pattern of β-D-galactopyranose, pentaacetate.The peak fragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 22 is a fragmentation pattern of D-mannitol hexaacetate. The peakfragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 23 is a fragmentation pattern of galacticol, hexaacetate. The peakfragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 24 is a fragmentation pattern of cyclohexane carboxylic acid,1,2,4,5-tetrakis(acetoxy), (1α,3α,4α,5β)-(-). The peak fragmentationpattern is in the top panel, the compound library fragmentation match isin the bottom panel, and an overlay of the two is in the center panel.

FIG. 25 is a fragmentation pattern of muco-inositol, hexaacetate. Thepeak fragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 26 is a fragmentation pattern of D-glucitol-hexaacetate. The peakfragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 27 is a fragmentation pattern of myo-inositol, hexaacetate. Thepeak fragmentation pattern is in the top panel, the compound libraryfragmentation match is in the bottom panel, and an overlay of the two isin the center panel.

FIG. 28 is an HPLC chromatogram of a 10% ACN extract of raw OrganicYellow potato.

FIG. 29 is an HPLC chromatogram of a 10% ACN extract of raw Purplepotato.

FIG. 30 is an HPLC chromatogram of a 10% ACN extract of raw Idaho Russetpotato.

FIG. 31 is an HPLC chromatogram of a 10% ACN extract of raw Yukon Goldpotato.

FIG. 32 is an HPLC chromatogram of a 10% ACN extract of raw sweetpotato.

FIG. 33 is an HPLC chromatogram of a 10% ACN extract of boiled Purplepotato.

FIG. 34 is an HPLC chromatogram of two pooled fraction collections fromIdaho Russet potatoes.

FIG. 35 is an HPLC chromatogram of fractions collections from 3 g ofpurple potatoes.

FIG. 36 is an HPLC chromatogram of media collected from cells exposed toa potato polysaccharide preparation for 4 hours.

FIG. 37 is a schematic of the study design used to test the use of apotato polysaccharide preparation to reduce diabetes and obesityparameters within living mammals.

FIG. 38 is a graph plotting mean body weights for ZDF rats (Fa/Fa) andlean ZDF rats (+/?) treated with vehicle or a potato polysaccharidepreparation (SNY).

FIG. 39 is a graph plotting mean triglyceride levels for ZDF rats(Fa/Fa) and lean ZDF rats (+/?) treated with vehicle or a potatopolysaccharide preparation (SNY).

FIG. 40 is a graph plotting mean LDL levels for ZDF rats (Fa/Fa) andlean ZDF rats (+/?) treated with vehicle or a potato polysaccharidepreparation (SNY).

FIG. 41 is a graph plotting mean serum glucose levels for ZDF rats(Fa/Fa) and lean ZDF rats (+/?) treated with vehicle or a potatopolysaccharide preparation (SNY).

FIG. 42 is a graph plotting mean water consumption levels for ZDF rats(Fa/Fa) and lean ZDF rats (+/?) treated with vehicle or a potatopolysaccharide preparation (SNY).

FIG. 43 is a graph plotting mean urine volumes for ZDF rats (Fa/Fa) andlean ZDF rats (+/?) treated with vehicle or a potato polysaccharidepreparation (SNY).

FIG. 44 is a graph plotting mean blood glucose levels for fasted ZDFrats (Fa/Fa) and fasted, lean ZDF rats (+/?) treated with vehicle or apotato polysaccharide preparation (SNY).

FIG. 45 is a graph plotting mean abdonminal fat weight to body weightratios for ZDF rats (Fa/Fa) and lean ZDF rats (+/?) treated with vehicleor a potato polysaccharide preparation (SNY).

FIG. 46 is a graph plotting mean kidney weight to body weight ratios forZDF rats (Fa/Fa) treated with vehicle or a potato polysaccharidepreparation (SNY).

FIG. 47 is a graph plotting mean liver weight to body weight ratios forZDF rats (Fa/Fa) and lean ZDF rats (+/?) treated with vehicle or apotato polysaccharide preparation (SNY).

FIG. 48 is a real time PCR amplification plot for TFAM demonstratingdifferences in threshold cycle numbers between potato polysaccharidepreparation-treated ZDF rats and untreated control ZDF rats. The lowercycle number for the treated rats equates to a higher gene expression.

FIG. 49 is a graph plotting the fold change in expression of TFAM intreated versus untreated rats.

DETAILED DESCRIPTION

This document provides methods and materials for treating diabetesand/or liver steatosis. For example, this document provides methods forusing compositions containing a potato polysaccharide preparation toreduce one or more symptoms of diabetes or liver steatosis. In somecases, a composition containing a potato polysaccharide preparationprovided herein can be used to reduce triglyceride levels, to reduceserum glucose levels, to reduce water consumption, to reduce urineproduction, to reduce kidney weight, to reduce liver weight, and/or toincrease abdominal fat. In some cases, a composition containing a potatopolysaccharide preparation provided herein can be used to treat fattyliver disease.

As described herein, a composition containing a potato polysaccharidepreparation provided herein (e.g., a nutritional supplement compositionprovided herein) can be administered to any appropriate mammal to reduceone or more symptoms of diabetes, liver steatosis, and/or fatty liverdisease. For example, a composition containing a potato polysaccharidepreparation provided herein can be administered to a rat, mouse, dog,cat, horse, cow, goat, pig, chicken, duck, rabbit, sheep, monkey, orhuman to reduce one or more symptoms of diabetes and/or liver steatosis.Examples of diabetes symptoms include, without limitation, excessivefluid intake, frequent urination, elevated blood glucose, elevatedurinary glucose, ketosis, and vascular degeneration. Examples of liversteatosis symptoms include, without limitation, hepatomegaly (enlargedliver), steatohepatitis, and malnutrition. Examples of fatty liverdisease symptoms include, without limitation, cirrhosis, jaundice, andesophageal bleeding.

Any appropriate route of administration (e.g., oral or parenteraladministration) can be used to administer a composition containing apotato polysaccharide preparation provided herein (e.g., a nutritionalsupplement composition provided herein) to a mammal. For example, acomposition containing a potato polysaccharide preparation providedherein can be administered orally.

A composition provided herein (e.g., a nutritional supplementcomposition) can include one or more potato polysaccharide preparations.A potato polysaccharide preparation can be a preparation that isobtained from a water extract of potato and that contains polysaccharidematerial having the ability to be eluted from a C18 cartridge (e.g., aSep-Pak Plus C-18 cartridge) with 10% acetonitrile. In some cases, apotato polysaccharide preparation can be a preparation that is obtainedfrom potato and that contains polysaccharide material having HPLCcharacteristics of that of the peak eluted at 3.5 minutes as describedin Example 1 (see, also, FIGS. 1, 2, and 28-34). In some cases, apolysaccharide of a potato polysaccharide preparation provided hereincan be a polar, water-soluble polysaccharide. In some cases, apolysaccharide of a potato polysaccharide preparation provided hereincan be a highly substituted complex xyloglucan material.

In some cases, a potato polysaccharide preparation can be a preparationthat is obtained from potato and that contains polysaccharide materialthat, when derivatized, results in at least the following acylatedcarbohydrates as assessed using GC/MS: (a) myo-inositol (set to 1× toserve as an internal standard), (b) glucose at about 40× to about 60×the myo-inositol content (e.g., glucose at about 50× the myo-inositolcontent), (c) xylose at about 10× to about 20× the myo-inositol content(e.g., xylose at about 15× the myo-inositol content), (d) mannose atabout 5× to about 15× the myo-inositol content (e.g., mannose at about10× the myo-inositol content), and (e) galactose at about 3× to about 7×the myo-inositol content (e.g., galactose at about 5× the myo-inositolcontent). The derivatization procedure can include forming a dry residueof the polysaccharide material that is then hydrolyzed usingtrifluoroacetic acid. The resulting material is then reduced usingsodium borohydride, and after borate removal, the end product isacylated using acetic anhydride and pyridine. The end products of thereaction are then injected directly on GC/MS to identify the acylatedcarbohydrates.

In some cases, a potato polysaccharide preparation can be a preparationthat is obtained from potato and that contains polysaccharide materialthat, when derivatized and assessed using GC/MS, results in at leastfour major components (3,4-furan dimethanol, diacetate;1,2,3,4,5-penta-o-acetyl-D-xylitol (isomer 1); 3,5-diacetoxy-benzylalcohol; and D-glucitol-hexaacetate). See, e.g., Example 1. In somecases, a potato polysaccharide preparation can be a preparation that isobtained from potato and that contains polysaccharide material that,when derivatized and assessed using GC/MS, results in the compoundslisted in Table 3 or results in the profile shown in FIG. 7.

In some cases, a potato polysaccharide preparation provided herein canbe a substantially pure potato polysaccharide preparation. Typically, asubstantially pure potato polysaccharide preparation is a preparationthat contains a single peak of material (e.g., a single peak ofpolysaccharide material) when assessed using, for example, HPLC (see,e.g., FIGS. 2 and 34). In some cases, greater than 60, 70, 75, 80, 85,90, 95, or 99 percent of a potato polysaccharide preparation providedherein can be polysaccharide material obtained from a potato.

Any appropriate potato species or variety can be used to obtain a potatopolysaccharide preparation provided herein. For example, Solanumtuberosum, Ipomoea batatas, S. acaule, S. bukasovii, S. leptophyes, S.megistacrolobum, S. commersonii, or S. infundibuliforme can be used toobtain a potato polysaccharide preparation provided herein. In somecases, potato varieties of S. tunerosum such as Organic Yellow, Purpleor blue varieties, Cream of the Crop, Adirondack Blue, Adirondack Red,Agata, Almond, Andes Gold, Andes Sun, Apline, Alturas, Amandine,Annabelle, Anya, Arran Victory, Atlantic, Avalanche, Bamberg, BannockRusset, Belle de Fontenay, BF-15, Bildtstar, Bintje, Blazer Russet, BlueCongo, Bonnotte, British Queens, Cabritas, Camota, Canela Russet, Cara,Carola, Chelina, Chiloé, Cielo, Clavela Blanca, Désirée, Estima, Fianna,Fingerling, Flava, German Butterball, Golden Wonder, Goldrush, HomeGuard, Innovator, Irish Cobbler, Jersey Royal, Kennebec, Kerr's Pink,Kestrel, Keuka Gold, King Edward, Kipfler, Lady Balfour, Langlade,Linda, Marcy, Marfona, Maris Piper, Marquis, Megachip, Monalisa, Nicola,Pachaconã, Pike, Pink Eye, Pink Fir Apple, Primura, Ranger Russet,Ratte, Record, Red LaSoda, Red Norland, Red Pontiac, Rooster, RussetBurbank, Russet Norkotah, Selma, Shepody, Sieglinde, Silverton Russet,Sirco, Snowden, Spunta, Up to date, Stobrawa, Superior, Vivaldi,Vitelotte, Yellow Finn, or Yukon Gold can be used to obtain a potatopolysaccharide preparation provided herein.

Any appropriate method can be used to obtain a potato polysaccharidepreparation provided herein. For example, raw potato material can behomogenized (e.g., homogenized with a Polytron homogenizer) in water andmaintained at room temperature for a period of time (e.g., about 1 hour)with occasional shaking. The homogenate can be centrifuged (e.g.,centrifuged at 4000 g for 10 minutes) to remove any larger solidmaterial. The resulting supernatant can be loaded onto a Solid PhaseExtraction cartridge (e.g., a C18 cartridge such as a Sep-Pak Plus C-18cartridge), and the polysaccharide material eluted with 10 percentacetonitrile. Once eluted, the polysaccharide material can be dried andstored (e.g., stored at about 4° C.).

This document also provides nutritional supplement compositionscontaining one or more potato polysaccharide preparations providedherein. For example, a potato polysaccharide preparation provided hereinobtained from Idaho Russet potatoes can be formulated into a nutritionalsupplement composition.

Any appropriate dose of a potato polysaccharide preparation providedherein can be used to formulate a composition provided herein (e.g., anutritional supplement composition or potato polysaccharide preparationprovided herein). For example, a potato polysaccharide preparationprovided herein can be used to formulate a composition for treatingdiabetes and/or liver steatosis such that the composition containsbetween about 1 mg and about 750 mg (e.g., between about 1 mg and about500 mg, between about 1 mg and about 250 mg, between about 5 mg andabout 40 mg, between about 5 mg and about 30 mg, between about 5 mg andabout 20 mg, between about 6 mg and about 50 mg, between about 6 mg andabout 20 mg, between about 10 mg and about 25 mg, or between about 15 mgand about 20 mg) of the potato polysaccharide component of the potatopolysaccharide preparation. In some cases, a composition (e.g., anutritional supplement composition) can be formulated to deliver about0.05 mg of the potato polysaccharide component per kg of body weight toabout 0.5 mg of the potato polysaccharide component per kg of bodyweight to a mammal (e.g., a human) per day. For example, a nutritionalsupplement composition can be formulated into a single oral compositionthat a human can swallow once a day to provide between about 0.05 mg ofthe potato polysaccharide component per kg of body weight to about 0.5mg of the potato polysaccharide component per kg of body weight.

Any appropriate method can be used to formulate a composition providedherein (e.g., a nutritional supplement composition or potatopolysaccharide preparation provided herein). For example, commonformulation mixing and preparation techniques can be used to make acomposition (e.g., a nutritional supplement composition) having thecomponents described herein. In addition, a composition provided herein(e.g., a nutritional supplement composition or potato polysaccharidepreparation provided herein) can be in any form. For example, acomposition provided herein (e.g., a nutritional supplement compositionor potato polysaccharide preparation provided herein) can be formulatedinto a pill, capsule, tablet, gelcap, nutritional shake, nutritionalbar, rectal supository, sublingual suppository, nasal spray, inhalant,or injectable ampule. In some cases, a composition provided herein(e.g., a nutritional supplement composition) can include one or morepotato polysaccharide preparations provided herein alone or incombination with other ingredients including, without limitation,gelatin, cellulose, starch, sugar, bentonite, lactic acid, mannitol,alpha lipoic acid, alpha tocopherol, L-ascorbate, or combinationsthereof.

This document also provides methods for increasing or decreasingexpression of polypeptides involved with mitochondria activity orfunction. For example, a potato polysaccharide preparation providedherein or a nutritional supplement composition provided herein can beused to increase or decrease expression of polypeptides involved withmitochondria activity or function. In some cases, a potatopolysaccharide preparation provided herein or a nutritional supplementcomposition provided herein can be used to increase expression of a TFAMpolypeptide, an ATP5A1 polypeptide, a PDHA1 polypeptide, a PDHA2polypeptide, a THOP1 polypeptide, or a combination thereof. In somecases, a potato polysaccharide preparation provided herein or anutritional supplement composition provided herein can be used todecrease expression of a FOX01A polypeptide, a NFKB1 polypeptide, a PDK2polypeptide, a PDK4 polypeptide, a HMGCR polypeptide, or a combinationthereof. In some case, a potato polysaccharide preparation providedherein or a nutritional supplement composition provided herein can beused to increase one or more polypeptides (e.g., one or more of a TFAMpolypeptide, an ATP5A1 polypeptide, a PDHA1 polypeptide, a PDHA2polypeptide, or a THOP1 polypeptide) and decrease one or morepolypeptides (e.g., one or more of a FOX01A polypeptide, a NFKB1polypeptide, a PDK2 polypeptide, a PDK4 polypeptide, or a HMGCRpolypeptide).

In humans, a potato polysaccharide preparation provided herein or anutritional supplement composition provided herein can be used toincrease one or more human polypeptides (e.g., one or more of a humanTFAM polypeptide, a human ATP5A1 polypeptide, a human PDHA1 polypeptide,a human PDHA2 polypeptide, a human THOP1 polypeptide, a human LIPEpolypeptide (in adipocytes), a human PCK2 polypeptide, a human MOGAT1polypeptide, a human PPARGC1a polypeptide, a vPPARGC1b polypeptide, anhuman SOD2 polypeptide, a human NR4A1 polypeptide (in adipocytes), ahuman ACAT2 polypeptide, or a human HMGCR polypeptide (in muscle cells))and/or decrease one or more human polypeptides (e.g., one or more of ahuman FOX01A polypeptide, a human NFKB1 polypeptide, a human PDK2polypeptide, a human PDK4 polypeptide, a human HMGCR polypeptide (inadipocytes), a human AGPAT1 polypeptide, a human OLR1 polypeptide, ahuman BCAT2 polypeptide, a human SH2B1 polypeptide, a human LPLpolypeptide, a human HMGCR polypeptide (in adipocytes), a human LIPEpolypeptide (in muscle cells), a human NR4A1 polypeptide (in musclecells), a human PTEN polypeptide, or a human CASP8 polypeptide).

A human TFAM polypeptide can have the amino acid sequence set forth inGenBank® Accession No. CAG28581.1 (GI No. 47115243) and can be encodedby the nucleic acid sequence set forth in GenBank® Accession No.NM_003201.1 (GI No. 4507400). A human ATP5A1 polypeptide can have theamino acid sequence set forth in GenBank® Accession No.AAH08028.2 (GINo. 34782901) and can be encoded by the nucleic acid sequence set forthin GenBank® Accession No. NM_001001937.1 (GI No. 50345983). A humanPDHA1 polypeptide can have the amino acid sequence set forth in GenBank®Accession No. ABQ58815.1 (GI No. 148300624) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_001173454.1(GI No. 291084741). A human PDHA2 polypeptide can have the amino acidsequence set forth in GenBank® Accession No. AAH94760.1 (GI No.66267554) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_005390.4 (GI No. 134031963). A human THOP1polypeptide can have the amino acid sequence set forth in GenBank®Accession No. AAH00583.2 (GI No. 38014202) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_003249.3(GI No. 34222291). A human LIPE polypeptide can have the amino acidsequence set forth in GenBank® Accession No. AAH70041.1 (GI No.47124456) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_005357.2 (GI No. 21328445). A human PCK2polypeptide can have the amino acid sequence set forth in GenBank®Accession No. CAG33194.1 (GI No. 48145943) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_004563.1(GI No. 66346720). A human MOGAT1 polypeptide can have the amino acidsequence set forth in GenBank® Accession No. NP_477513.2 (GI No.148746191) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_058165.1 (GI No. 148746190). A human PPARGC1apolypeptide can have the amino acid sequence set forth in GenBank®Accession No. NP_037393.1 (GI No. 7019499) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_013261.2(GI No. 116284374). A human PPARGC1b polypeptide can have the amino acidsequence set forth in GenBank® Accession No. AAI44252.1 (GI No.219518198) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_133263.2 (GI No. 289577087). A human SOD2polypeptide can have the amino acid sequence set forth in GenBank®Accession No. AAH16934.1 (GI No. 16877367) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_000636.1(GI No. 67782304). A human NR4A1 polypeptide can have the amino acidsequence set forth in GenBank® Accession No. CAG32985.1 (GI No.48145525) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_173158.1 (GI No. 320202954). A human ACAT2polypeptide can have the amino acid sequence set forth in GenBank®Accession No. AAH00408.1 (GI No. 12653279) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_005891.1(GI No. 148539871). A human FOX01A polypeptide can have the amino acidsequence set forth in GenBank® Accession No. NP_002006.2 (GI No.9257222) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_002015.3 (GI No. 133930787). A human NFKB1polypeptide can have the amino acid sequence set forth in GenBank®Accession No. CAB94757.1 (GI No. 8574070) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_001165412.1(GI No. 25955301). A human PDK2 polypeptide can have the amino acidsequence set forth in GenBank® Accession No. NP_002602.2 (GI No.19923736) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_00211.4 (GI No. 315630394). A human PDK4polypeptide can have the amino acid sequence set forth in GenBank®Accession No. AAH40239.1 (GI No. 25955471) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_002612.2(GI No. 94421466). A human HMGCR polypeptide can have the amino acidsequence set forth in GenBank® Accession No. AAH33692.1 (GI No.21707182)and can be encoded by the nucleic acid sequence set forth in GenBank®Accession No. NM_000859.2 (GI No. 196049378). A human AGPAT1 polypeptidecan have the amino acid sequence set forth in GenBank® Accession No.NP_116130.2 (GI No. 15100175) and can be encoded by the nucleic acidsequence set forth in GenBank® Accession No. NM_006411.3 (GI No.301336168). A human OLR1 polypeptide can have the amino acid sequenceset forth in GenBank® Accession No. NP_002534.1 (GI No. 4505501) and canbe encoded by the nucleic acid sequence set forth in GenBank® AccessionNo. NM_002543.2 (GI No. 119392084). A human BCAT2 polypeptide can havethe amino acid sequence set forth in GenBank® Accession No. AAH04243.2(GI No. 48257075) and can be encoded by the nucleic acid sequence setforth in GenBank® Accession No. NM_001190.1 (GI No. 258614013). A humanSH2B1 polypeptide can have the amino acid sequence set forth in GenBank®Accession No. AAH10704.1 (GI No. 14715079) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_001145797.1(GI No. 224926829). A human LPL polypeptide can have the amino acidsequence set forth in GenBank® Accession No. CAG33335.1 (GI No. 4814622)and can be encoded by the nucleic acid sequence set forth in GenBank®Accession No. NM_000237.1 (GI No. 145275217). A human HMGCR polypeptidecan have the amino acid sequence set forth in GenBank® Accession No.AAH33692.1 (GI No. 21707182) and can be encoded by the nucleic acidsequence set forth in GenBank® Accession No. NM_001130996.1 (GI No.196049379). A human PTEN polypeptide can have the amino acid sequenceset forth in GenBank® Accession No. AAD13528.1 (GI No. 4240387) and canbe encoded by the nucleic acid sequence set forth in GenBank® AccessionNo. NM_000314.2 (GI No. 110224474). A human CASP8 polypeptide can havethe amino acid sequence set forth in GenBank® Accession No. AAH68050.1(GI No. 45751586) and can be encoded by the nucleic acid sequence setforth in GenBank® Accession No. NM_001228.4 (GI No. 122056470).

In addition, this document provides methods for increasing expression ofpolypeptides involved in mitochondrial biogenesis linked to enhancedprotein and nucleic acid biosynthesis. For example, a potatopolysaccharide preparation provided herein or a nutritional supplementcomposition provided herein can be used to increase expression ofpolypeptides involved with mitochondrial biogenesis linked to enhancedprotein and nucleic acid biosynthesis. In some cases, a potatopolysaccharide preparation provided herein or a nutritional supplementcomposition provided herein can be used to increase expression of aSlc25a33 polypeptide, an Tomm40 polypeptide, a Mrpl3 polypeptide, aMrps18b polypeptide, a Mrps9 polypeptide, a Fars2 polypeptide, a Mrpl15polypeptide, a Mrps23 polypeptide, a Mrps2 polypeptide, a Mrpl17polypeptide, a TFAM polypeptide, or a combination thereof.

This document also provides methods for increasing expression ofpolypeptides involved in mitochondrial energy production. For example, apotato polysaccharide preparation provided herein or a nutritionalsupplement composition provided herein can be used to increaseexpression of polypeptides involved with mitochondrial energyproduction. In some cases, a potato polysaccharide preparation providedherein or a nutritional supplement composition provided herein can beused to increase expression of a Prodh polypeptide, an Slc25a1polypeptide, a Hmgcl polypeptide, a Cps1 polypeptide, a Aldh4a1polypeptide, a Mdh2 polypeptide, a Atp5b polypeptide, a Slc25a22polypeptide, a Slc25a19 polypeptide, a Uqcrc2 polypeptide, a Abcf2polypeptide, or a combination thereof.

This document also provides methods for increasing or decreasingexpression of polypeptides involved with lipogenesis, triglycerideassembly, and mitochondrial lipolysis. For example, a potatopolysaccharide preparation provided herein or a nutritional supplementcomposition provided herein can be used to increase or decreaseexpression of polypeptides involved with lipogenesis, triglycerideassembly, and mitochondrial lipolysis. In some cases, a potatopolysaccharide preparation provided herein or a nutritional supplementcomposition provided herein can be used to increase expression of anAcbd4 polypeptide, a Fads1 polypeptide, a Gnpat polypeptide, a Lypla1polypeptide, a Cpt2 polypeptide, or a combination thereof. In somecases, a potato polysaccharide preparation provided herein or anutritional supplement composition provided herein can be used todecrease expression of a Pck2 polypeptide, an Agpat4 polypeptide, anAcaca polypeptide, or a combination thereof. In some case, a potatopolysaccharide preparation provided herein or a nutritional supplementcomposition provided herein can be used to increase one or morepolypeptides (e.g., one or more of an Acbd4 polypeptide, a Fads1polypeptide, a Gnpat polypeptide, a Lypla1 polypeptide, a Cpt2polypeptide) and decrease one or more polypeptides (e.g., one or more ofa Pck2 polypeptide, an Agpat4 polypeptide, an Acaca polypeptide).

In humans, a potato polysaccharide preparation provided herein or anutritional supplement composition provided herein can be used toincrease one or more human polypeptides (e.g., one or more of a Slc25a33polypeptide, an Tomm40 polypeptide, a Mrpl3 polypeptide, a Mrps18bpolypeptide, a Mrps9 polypeptide, a Fars2 polypeptide, a Mrpl15polypeptide, a Mrps23 polypeptide, a Mrps2 polypeptide, a Mrpl17polypeptide, a TFAM polypeptide, a Prodh polypeptide, an Slc25a1polypeptide, a Hmgcl polypeptide, a Cps1 polypeptide, a Aldh4a1polypeptide, a Mdh2 polypeptide, an Atp5b polypeptide, a Slc25a22polypeptide, a Slc25a19 polypeptide, a Uqcrc2 polypeptide, an Abcf2polypeptide, an Acbd4 polypeptide, a Fads1 polypeptide, a Gnpatpolypeptide, a Lypla1 polypeptide, and a Cpt2 polypeptide (in livercells)) and/or decrease one or more human polypeptides (e.g., one ormore of a Pck2 polypeptide, an Agpat4 polypeptide, and an Acacapolypeptide (in liver cells)).

A human Slc25a33 polypeptide can have the amino acid sequence set forthin GenBank® Accession No. XP_005263560.1 (GI No. 530360655) and can beencoded by the nucleic acid sequence set forth in GenBank® Accession No.XM_005263503.1 (GI No. 530360654). A human Tomm40 polypeptide can havethe amino acid sequence set forth in GenBank® Accession No. AAH47528.1(GI No. 28839408) and can be encoded by the nucleic acid sequence setforth in GenBank® Accession No. NM_001128916.1 (GI No. 193083119). Ahuman Mrpl3 polypeptide can have the amino acid sequence set forth inGenBank® Accession No. CAG33001.1 (GI No. 48145557) and can be encodedby the nucleic acid sequence set forth in GenBank® Accession No.NM_007208.3 (GI No. 312147300). A human Mrps18b polypeptide can have theamino acid sequence set forth in GenBank® Accession No. BAD13700.1 (GINo. 46091143) and can be encoded by the nucleic acid sequence set forthin GenBank® Accession No. NM_014046.3 (GI No. 186928836). A human Mrps9polypeptide can have the amino acid sequence set forth in GenBank®Accession No. AAH47784.1 (GI No. 29126836) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_182640.2(GI No. 186910309). A human Fars2 polypeptide can have the amino acidsequence set forth in GenBank® Accession No. NP_006558.1 (GI No.5729820) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_006567.3 (GI No. 126513133). A human Mrpl15polypeptide can have the amino acid sequence set forth in GenBank®Accession No. CAG38562.1 (GI No. 49065488) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_014175.3(GI No. 169403971). A human Mrps23 polypeptide can have the amino acidsequence set forth in GenBank® Accession No. NP_057154.2 (GI No.16554604) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_016070.3 (GI No. 312222785). A human Mrps2polypeptide can have the amino acid sequence set forth in GenBank®Accession No. AAH04905.2 (GI No. 33872889) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_016034.4(GI No. 389565494). A human Mrpl17 polypeptide can have the amino acidsequence set forth in GenBank® Accession No. CAG33458.1 (GI No.48146471) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_022061.3 (GI No. 169403966). A human Prodhpolypeptide can have the amino acid sequence set forth in GenBank®Accession No. AAD24775.1 (GI No. 4581877) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_016335.4(GI No. 304766735). A human Slc25a1 polypeptide can have the amino acidsequence set forth in GenBank® Accession No. NP_005975.1 (GI No.21389315) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_005984.3 (GI No. 374713106). A human Hmgclpolypeptide can have the amino acid sequence set forth in GenBank®Accession No. CAG33165.1 (GI No. 48145885) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_000191.2(GI No. 62198231). A human Cps1 polypeptide can have the amino acidsequence set forth in GenBank® Accession No. AAH20695.1 (GI No.116283350) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_001122633.2 (GI No. 327532712). A humanAldh4a1 polypeptide can have the amino acid sequence set forth inGenBank® Accession No. ACN89883.1 (GI No. 225421341) and can be encodedby the nucleic acid sequence set forth in GenBank® Accession No.FJ462711.1 (GI No. 225421340). A human Mdh2 polypeptide can have theamino acid sequence set forth in GenBank® Accession No. CAG38785.1 (GINo. 49168580) and can be encoded by the nucleic acid sequence set forthin GenBank® Accession No. CR536548.1 (GI No. 49168579). A human Atp5bpolypeptide can have the amino acid sequence set forth in GenBank®Accession No. ABD77240.1 (GI No. 89574029) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_001686.3(GI No. 50345985). A human Slc25a22 polypeptide can have the amino acidsequence set forth in GenBank® Accession No. NP_001177990.1 (GI No.300796991) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_001191060.1 (GI No. 300796969). A humanSlc25a19 polypeptide can have the amino acid sequence set forth inGenBank® Accession No. NP_001119594.1 (GI No. 186928860) and can beencoded by the nucleic acid sequence set forth in GenBank® Accession No.NM_001126121.1 (GI No. 186928857). A human Uqcrc2 polypeptide can havethe amino acid sequence set forth in GenBank® Accession No. AAH00484.1(GI No. 12653427) and can be encoded by the nucleic acid sequence setforth in GenBank® Accession No. NM_003366.2 (GI No. 50592987). A humanAbcf2 polypeptide can have the amino acid sequence set forth in GenBank®Accession No. NP_009120.1 (GI No. 27881506) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. NM_007189.2(GI No. 525345247). A human Acbd4 polypeptide can have the amino acidsequence set forth in GenBank® Accession No. AAH41143.1 (GI No.26996542) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_001135704.1 (GI No. 209364588). A human Fads1polypeptide can have the amino acid sequence set forth in GenBank®Accession No. AFL91689.1 (GI No. 390432195) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. AK314199.1 (GINo. 164697148). A human Gnpat polypeptide can have the amino acidsequence set forth in GenBank® Accession No. NP_055051.1 (GI No.7657134) and can be encoded by the nucleic acid sequence set forth inGenBank® Accession No. NM_014236.3 (GI No. 170650722). A human Lypla1polypeptide can have the amino acid sequence set forth in GenBank®Accession No. CAG33384.1 (GI No. 48146323) and can be encoded by thenucleic acid sequence set forth in GenBank® Accession No. CR457103.1 (GINo. 48146322). A human Cpt2 polypeptide can have the amino acid sequenceset forth in GenBank® Accession No. NP_000089.1 (GI No. 4503023) and canbe encoded by the nucleic acid sequence set forth in GenBank® AccessionNo. NM_000098.2 (GI No. 169790951). A human Agpat4 polypeptide can havethe amino acid sequence set forth in GenBank® Accession No. AAH13410.1(GI No. 38196950) and can be encoded by the nucleic acid sequence setforth in GenBank® Accession No. XM_005267052.1 (GI No. 530383869). Ahuman Acaca polypeptide can have the amino acid sequence set forth inGenBank® Accession No. AAH31485.1 (GI No. 32425437) and can be encodedby the nucleic acid sequence set forth in GenBank® Accession No.XM_005257266.1 (GI No. 530412017).

The potato polysaccharide preparations provided herein or nutritionalsupplement compositions provided herein can be administered to anyappropriate mammal (e.g., rat, mouse, dog, cat, horse, cow, goat, pig,chicken, duck, rabbit, sheep, monkey, or human). In addition, anyappropriate route of administration (e.g., oral or parenteraladministration) can be used to administer a potato polysaccharidepreparation provided herein or a nutritional supplement compositionprovided herein to a mammal. For example, a potato polysaccharidepreparation provided herein or a nutritional supplement compositionprovided herein can be administered orally.

The document will provide addition description in the followingexamples, which do not limit the scope of the invention described in theclaims.

EXAMPLES Example 1 Identification of a Potato Polysaccharide PreparationHaving the Ability to Alter Expression of Polypeptides Involved withMitochondria Activity and Function

6 grams of a Russet potato variety of the Solanum tuberosum species werehomogenized with a Polytron homogenizer in 20 mL water in a 50 mLcentrifuge tube and kept at room temperature for 1 hour. The homogenatewas centrifuged at 4000 rpm for 10 minutes. A Sep-Pak Plus C-18cartridge was activated with 10 mL 100% acetonitrile (ACN) and washedwith 10 mL 0.05% trifluoroacetic acid in water (TFA water). 10 mL of thesupernatant was loaded onto the cartridge, and all H₂O that passesthrough cartridge was collected in 1.5 mL Eppendorf tubes. Next, 10 mLof 2% ACN (in 0.05% TFA water) was passed through the column, and theelutriate was collected in 1.5 mL Eppendorf tubes. Next, 10 mL of 5% ACN(in 0.05%TFA water) was used to wash the column, and the elutriate wascollected in 1.5 mL Eppendorf tubes. Finally, 10 mL of 10% ACN (in 0.05%TFA water) was collected in 1.5 mL Eppendorf tubes after passing throughthe column. All of the fractions were dried, and the dried fractions ofthe same ACN concentration were reconstituted into 1 tube in 1 mL of0.05% TFA water for further purification via HPLC or reconstituted in 1mL of phosphate buffered saline for use in cell treatments.

A Waters 2695 separations module with a photodiode array detector wasused to purify the 10% ACN extract. An XterraRP C18 column (4.6×150 mm)was used for the separation with 0.05% TFA water as the mobile phase.Each HPLC run was a 20 minute gradient ranging from 0 to 2.5% ACN. Theinjection volume was 100 μL, and the flow rate was 0.5 mL/minute. HPLCfractionation of the 10% ACN extract yielded three major UV absorbingpeaks eluted at 3.5, 3.9, and 12.1 minutes (FIG. 1). Collection and HPLCre-purification of the 3.5 minute fraction yielded a symmetrical peakdisplaying a maximum absorbance at 198.3 nm (FIG. 2).

The three peaks were evaluated to determine whether or not they obtainedmaterial having the ability to alter the expression levels ofpolypeptides involved in mitochondria activity and function. Briefly,5×10⁵ neuroblastoma cells obtained from American Type Culture Collection(ATCC) were plated into each well of 6-well plates with 2 mL of RPMImedia and incubated for 4 hours in the presence or absence of differentaliquots of the HPLC purified material. Following the incubation, totalRNA was isolated and purified using the RNeasy mini kit (Qiagen,Valencia, Calif.). In particular, pelleted cells were resuspended in 600μL of RLT lysis buffer (Qiagen) and homogenized by passing the lysate 20times through a 1 mL pipette tip. The samples were then processedaccording to the manufacturer's instructions (Qiagen, Valencia, Calif.).In the final step, the RNA was eluted with 40 μL of RNase-free water bycentrifugation for 1 minute at 13,000 g. The RNA was analyzed on a model2100 bioanalyzer (Agilent, Santa Clara, Calif.) using a total RNAnanochip according to the manufacturer's protocol. Afterwards, 2 μg oftotal RNA was reverse transcribed using Superscript III reversetranscriptase and random primers.

DNA microarray analyses also were performed using a system provided byAgilent. Arrays included four arrays per chip (Agilent 4X44K chips).Total RNA was reverse transcribed (400 ng) using T7 primers and labeledand transcribed using Cyanine-3 dye. Each array was hybridized with atleast 1.65 μg of labeled cRNA at 65° C. for 18 hours. Arrays werescanned using an Agilent array scanner. A 10% or greater change in geneexpression was capable of being determined using both microarrayplatforms.

Incubation of cultured cells with the HPLC purified fraction eluted at3.5 minutes produced changes in the expression of mitochondrial andcellular metabolic genes (Table 1). The extracted potato material thateluted at 3.5 minutes is referred to herein as potato polysaccharidematerial, a potato polysaccharide preparation, or a potatopolysaccharide since it was determined to be a polysaccharide asindicated below. The 3.5 minute fraction (a potato polysaccharidepreparation) was the only fraction of the three determined to possesssignificant biological activity when tested using real time PCR forTFAM, NFKB, and HMGCR expression.

TABLE 1 Gene expression changes in HTB-11 cells as determined bymicroarray following a four-hour incubation with a potato polysaccharidepreparation. Gene % symbol Gene name change TFAM transcription factor A,mitochondrial +15 FOX01A forkhead box O1 −28 NFKB1 nuclear factor ofkappa light polypeptide gene −14 enhancer in B-cells 1 ATP5A1 ATPsynthase, H+ transporting, mitochondrial F1 +30 complex, alpha subunit 1PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1  +8 PDHA2 pyruvatedehydrogenase (lipoamide) alpha 2 +41 PDK2 pyruvate dehydrogenasekinase, isozyme 2 −24 PDK4 pyruvate dehydrogenase kinase, isozyme 4 −41HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase −18 THOP1 thimetoligopeptidase 1 +23

Real-time PCR was performed in triplicate with TFAM, HMGCR, and NFKB1detector sets. Beta-actin or GAPDH was used as a reference gene. Thereal-time PCR master mix included 25 μL 2× universal master mix, 2.5 μL20× detector set (with the primer and probe), and 21.50 μL of water. PCRwas performed in an Applied Biosystems 7500 sequence detection system.The thermocycler conditions included denaturation at 95° C. for 15seconds and annealing/extension at 60° C. for 60 seconds. Forty cyclesof PCR were preceded by 95° C. for 10 minutes. Reactions were performedin triplicate. The relative quantities of TFAM were found using theformula 2^(−ΔΔCt) using the Applied Biosystems 7500 software. Validationof some of the microarray results by real time PCR used TFAM, HMGCR, andNFKB1 as candidate genes. A representative real time PCR amplificationplot demonstrated that TFAM mRNA was present and was differentiallyexpressed (FIG. 3). The potato polysaccharide preparation had a profoundeffect on TFAM expression and was able to upregulate it by 57% (Table2). Both HMGCR and NFKB1 gene expression were reduced by approximately20%, consistent with and validating the DNA microarray data (Table 2).

TABLE 2 Validation of gene expression changes by real time PCR. HTB-11cells treated for 4 hours with a potato polysaccharide preparation. GeneSymbol % change TFAM +57 ± 9 NFKB1 −20 ± 5 HMGCR −19 ± 4

Further chemical characterization of the symmetrical 3.5 minute HPLCpeak material was performed. Pooled 3.5 minute HPLC fractions were driedand reconstituted in 1 mL TFA water and subjected to tandem LC/MS/MS(FIG. 4) and NMR chemical analyses (FIGS. 5 and 6). For the NMRanalysis, ¹H-NMR was run on the sample using deuterium oxide (D₂O) as asolvent to further analyze the sample. The water peak at 4.65 PPM wassolvent-suppressed, and the spectrum was acquired for several hours.Acetamide was detected at 3.2 PPM, along with acetonitrile at 1.9 PPM.Minor peaks were detected at 1.05 PPM, 1.17 PPM (broad peak), 1.189 PPM,and 1.864 PPM. One characteristic of polymeric materials in a proton NMRwas the broadening of peaks such as the shift at 1.17 PPM. These shiftson the NMR could represent the peak at 4.8 PPM and suggested a polar,water-soluble polymer such as a polysaccharide. Taken together, theseresults confirmed the presence of high molecular weight polysaccharidematerial contained in HPLC purified fractions eluting at 3.5 minutes.

Further analysis confirmed that the HPLC purified fraction eluting at3.5 minutes contains polysaccharide material (e.g., highly substitutedcomplex xyloglucan material). To make the polysaccharide materialanalyzable by gas chromatography/mass spectroscopy (GC/MS), it wasconverted into its derivatized carbohydrate fragments. Briefly, thesample was concentrated to a dry residue that was hydrolyzed usingtrifluoroacetic acid. This was then reduced using sodium borohydride,and after borate removal, the end product was acylated using aceticanhydride and pyridine. The end products of the reaction were injecteddirectly on GC/MS to identify any acylated carbohydrates. Based on theend analysis, a larger carbohydrate existed in the sample. The total ionchromatogram (TIC) is shown below in FIG. 7 with appropriate peak labelsbelow in Table 3. The major components identified are indicated in bold(peaks 3, 12, 14, and 21). The corresponding fragmentation for eachcompound is provided in FIGS. 8-27. For each fragmentation, the peakfragmentation pattern is on the top, the compound library fragmentationmatch is on the bottom, and an overlay of the two is in the center.Finally, unlabeled peaks were either column bleed or did not have asufficient match to the compound library.

TABLE 3 Summary of GC/MS results. Retention Time Peak (min) CompoundName Structure 1 10.731 Diacetamide

2 13.669 3-Acetoxy pyridine

3 19.568 3,4-Furan dimethanol, diacetate

4 19.950 1,2,3-propanetriol diacetate

5 23.387 Imidazole, 2- acetamino-5-methyl

6 23.499 6,7-dihydro-5H- pyrrol[2,1,c][1,2,4] triazole-3-carboxylic acid

7 24.304 Acetic acid, 1-(2- methyltetrazol-5-yl) ethenyl ester

8 25.538 1,2,3,4-butanetriol, tetraacetate

9 27.412 (1,5)β(1,3)triacetyl D-galactosan (stereoisomer 1)

10 28.188 (1,5)β(1,3)triacetyl D-galactosan (stereoisomer 2)

11 29.210 Pentaerythritol tetraacetate

12 29.727 1,2,3,4,5-penta-o- acetyl-D-xylitol (isomer 1)

13 30.697 1,2,345-penta-o- acetyl-D-xylitol (isomer 2)

14 32.477 3,5-diacetoxy-benzyl alcohol

15 32.677 β-D-glucopyranose, pentaacetate

16 33.012 D-mannitol hexaacetate

17 33.106 β-D-galactopyranose, pentaacetate

18 33.206 Galacticol, hexaacetate

19 33.364 Cyclohexane carboxylic acid, 1,2,45- tetrakis(acetoxy),(1α,3α,4α,5β)-(−)

20 33.582 Muco-inositol, hexaacetate

21 33.006 D-glucitol- hexaacetate

22 34.463 Myo-inositol, hexaacetate

These results demonstrate the presence of sugar monomers that serve asbuilding blocks for a larger carbohydrate. It appeared from thesemultiple lines of analysis that the potato polysaccharide preparation isa highly substituted complex xyloglucan.

Example 2 Sweet Potatoes and Multiple Varieties of Potatoes Exhibit thePresence of Potato Polysaccharide Material

Six grams of potato material from multiple varieties of Solanumtuberosum (Organic yellow, Purple, Idaho Russet, and Yukon Gold) and sixgrams of material from sweet potatoes (Ipomoea batatas) were extractedin 20 mL of water. 10 mL of that water was then loaded onto a sep-pakcartridge, and the cartridge was then eluted with 10 mL of 10% ACN. TheACN was then dried, and the residue was dissolved in 1 mL of water. A100 μL injection of this water was assessed using HPLC.

The HPLC chromatograms demonstrated that the amount of the first peak(at 3.5 minutes at 210 nm) was the same for all five types of potatoestested (FIGS. 28-32).

In another experiment, material was extracted from a boiled Purplepotato and analyzed. The peak at 3.5 minutes was not reduced in theboiled potato (FIG. 33).

The 3.5 minute peak from two pooled fraction collections from IdahoRusset potatoes was collected, dried, and reconstituted in 100 μL ofwater. The material was then injected into the HPLC yielding a singlepeak at 3.5 minutes (FIG. 34). Taken together, these results demonstratethat potatoes within the Solanum tuberosum and Ipomoea batatas speciescontain potato polysaccharide material.

Example 3 Highly Substituted Complex Xyloglucan from Potato MaterialAlters Expression of Polypeptides in Human Omental Apidocytes Obtainedfrom Diabetic Patients

Human omental apidocytes obtained from normal and diabetic patients werepurchased from Zen-Bio, Inc (Research Triangle Park, N.C.). The cellswere either untreated or treated with 62.5 μg/mL of the 3.5 minute peakfrom purple potatoes for four hours. After the four hour incubations,the cells were harvested, and a microarray analysis was performed tomeasure changes in gene expression.

Incubation of human omental apidocytes from diabetic patients with theHPLC purified fraction eluted at 3.5 minutes produced changes in theexpression of genes involved in obesity and/or diabetes (Table 4).Incubation of human omental apidocytes from normal humans producedminimal changes in the expression of the genes listed in Table 4 (Table5).

TABLE 4 Gene expression changes as determined by microarray following afour-hour incubation of human omental apidocytes from diabetic patientswith a potato polysaccharide preparation. Gene symbol % change AGPAT1 −1 OLR1 −45 BCAT2  −9 NFKB1  −6 SH2B1 −17 LPL −24 HMGCR  −9 LIPE +15PCK2  +5 MOGAT1 +52 PPARGC1a +59 PPARGC1b +44 SOD2 +18 NR4A1 +12 ACAT2+13

TABLE 5 Gene expression changes as determined by microarray following afour-hour incubation of human omental apidocytes from normal humans witha potato polysaccharide preparation. Gene symbol % change AGPAT1 Nonedetected OLR1 −18 BCAT2 None detected NFKB1 −56 SH2B1 −33 LPL +18 HMGCR+16 LIPE +32 PCK2 +30 MOGAT1 +22 PPARGC1a +26 PPARGC1b +26 SOD2 +23NR4A1 +45 ACAT2 +17

Real-time PCR was performed in triplicate with AGPAT1, OLR1, BCAT2,NR4A1, and ACAT2 detector sets. Beta-actin or GAPDH was used as areference gene. The real-time PCR master mix included 25 μL 2× universalmaster mix, 2.5 μL 20× detector set (with the primer and probe), and21.5 μL of water. PCR was performed in an Applied Biosystems 7500sequence detection system. The thermocycler conditions includeddenaturation at 95° C. for 15 seconds and annealing/extension at 60° C.for 60 seconds. Forty cycles of PCR were preceded by 95° C. for 10minutes. Reactions were performed in triplicate. Validation of some ofthe microarray results by real time PCR used AGPAT1, OLR1, BCAT2, NR4A1,and ACAT2 as candidate genes. Real time PCR amplification plotsdemonstrated that AGPAT1, OLR1, BCAT2, NR4A1, and ACAT2 mRNAs werepresent and were differentially expressed (Table 6).

TABLE 6 Validation of gene expression changes by real time PCR. Humanomental apidocytes from diabetic patients treated for 4 hours with apotato polysaccharide preparation. Gene Symbol % change AGPAT1 −13 ± 1OLR1  −9 ± 1 BCAT2  −4 ± 1 NR4A1 +34 ± 3 ACAT2 +12 ± 2

Example 4 Highly Substituted Complex Xyloglucan from Potato MaterialAlters Expression of Polypeptides in Mouse Myocytes

Mouse myoblasts were seeded in 2 mL aliquots into two 75 cm² tissueculture flasks. Cells were left to differentiate into myocytes for 4days in 5% CO₂ at 37° C.

Myocytes were detached from flask walls using gentle agitation.Suspended cells were transferred to a 15 mL conical tube and centrifugedat 500 g for 3 minutes. 2 mL aliquots were seeded into 75 cm² tissueculture flasks for both control and diabetic model cells. The mousecells were obtained from normal mice and from mice treated with low dosealloxan. The diabetic mice had high blood glucose compared to the normalmice. A potato polysaccharide preparation (62.5 μg/mL of the 3.5 minutepeak from purple potatoes) was added to one control and one diabeticflask, and the cells were incubated for 24 hours.

After the 24 hour incubation, the cells were harvested, and a microarrayanalysis was performed to measure changes in gene expression. Inaddition, images were taken of the cells after treatment using a NikonEclipseTE300 (Morell) inverted microscope coupled with an Optronicsdigital cameraware at 20×. The images were analyzed on ImageJ softwarefor cell mortality and fiber size. Cell mortality was calculated using aratio of the number of inactive cells to the number of active cells.Fiber size was calculated using a polygonal lasso tracer and measured inpixel area.

Incubation of mouse myocytes from the diabetic model with the HPLCpurified fraction eluted at 3.5 minutes produced changes in theexpression of genes involved in obesity and/or diabetes (Table 7).Incubation of mouse myocytes from normal mice produced minimal changesin the expression of the genes listed in Table 7 (Table 8).

TABLE 7 Gene expression changes as determined by microarray following a24-hour incubation of mouse myocytes from the diabetic model with apotato polysaccharide preparation. Gene symbol % change NFKB1 −46 SH2B1−35 LPL −16 HMGCR +25 LIPE −46 PCK2 none SOD2 +74 NR4A1 −33 ACAT2 nonePTEN −22 CASP8 not detected

TABLE 8 Gene expression changes as determined by microarray following a24-hour incubation of mouse myocytes from normal mice with a potatopolysaccharide preparation. Gene symbol % change NFKB1 37 SH2B1 202 LPL139 HMGCR 105 LIPE 147 PCK2 118 SOD2 None detected NR4A1 200 ACAT2 75PTEN 96 CASP8 104

Real-time PCR was performed in triplicate with PTEN and CASP8 detectorsets. Beta-actin or GAPDH was used as a reference gene. The real-timePCR master mix included 25 μL 2× universal master mix, 2.5 μL 20×detector set (with the primer and probe), and 21.5 μL of water. PCR wasperformed in an Applied Biosystems 7500 sequence detection system. Thethermocycler conditions included denaturation at 95° C. for 15 secondsand annealing/extension at 60° C. for 60 seconds. Forty cycles of PCRwere preceded by 95° C. for 10 minutes. Reactions were performed intriplicate. Validation of some of the microarray results by real timePCR used PTEN and CASP8 as candidate genes. Real time PCR amplificationplots demonstrated that PTEN and CASP8 mRNAs were present and weredifferentially expressed (Table 9).

TABLE 9 Validation of gene expression changes by real time PCR. Mousemyocytes from the diabetic model treated for 24 hours with a potatopolysaccharide preparation. Gene Symbol % change PTEN −31 ± 4 CASP8 −72± 8

Example 5 Analysis of a Potato Polysaccharide Preparation

A potato polysaccharide preparation was purified using HPLC from 3 g ofpurple potato. The potato polysaccharide peak was eluted at about 5minutes (FIG. 35). This peak was obtained using a differentchromatographic column (10 mm×150 mm) as compared to the column used toobtain the 3.5 minute peak. Since the column was a larger preparativecolumn and the flow rate was 1.5 mL/minute, the elution time of thepotato polysaccharide was 5 minutes.

The obtained peak was collected, dried, and reconstituted in 60 μL ofwater. The reconstituted potato polysaccharide material was then addedto HTB-11 cells in culture flasks for 4 hours. The post treatment mediawas collected and added to another flask of HTB-11 cells. Each group ofcells was analyzed for gene expression changes. The initially treatedcells exhibited the expected changes in mitochondrial gene expression.No changes were detected in the cells exposed to the post treatmentmedia for 4 hours.

In a separate experiment, the post treatment media was extracted usingthe techniques used to originally purify the potato polysaccharide. Achromatogram of the extracted post treatment media demonstrated theabsence of a peak at 5 minutes.

Example 6 Using a Potato Polysaccharide Preparation to Treat ObesityClass I-III Obese Humans are Identified Based on the Criteria of Table10

TABLE 10 Classification of Overweight and Obesity by BMI, WaistCircumference, and Associated Disease Risks. Disease Risk* Relative toNormal Weight and Waist Circumference Men 102 cm (40 in) Men > 102 cm orless (40 in) BMI Obesity Women 88 cm (35 in) Women > 88 cm (kg/m²) Classor less (35 in) Underweight <18.5 — — Normal 18.5- — — 24.9 Overweight25.0- Increased High 29.9 Obesity 30.0- I High Very High 34.9 35.0- IIVery High Very High 39.9 Extreme 40.0+ III Extremely High Extremely HighObesity

Once identified, a Class I-III obese patient is treated as follows.Potato polysaccharide is formulated in the presence of alpha lipoic acidor alpha tocopherol or both. Formulated potato polysaccharide is addedto 90% by weight inert binder material and is administered by the oralparenteral route in the form of a tablet, capsule, or liquid, twicedaily (bid). Maximal concentrations of potato polysaccharide areinitially administered bid over the course of one month. Positiveoutcome measures include: (1) significant reduction of BMI, (2)augmentation of serum LDL/HDL ratio, (3) lowering serum triglycerideconcentration, (4) lowering systolic and diastolic blood pressure, and(5) lowering fasting blood glucose.

Example 7 Using a Potato Polysaccharide Preparation to Treat Type IIDiabetes

Once a type II diabetes patient is identified, the patient is treated asfollows. Potato polysaccharide is formulated in the presence of alphalipoic acid or alpha tocopherol or both. Formulated potatopolysaccharide is added to 90% by weight inert binder material and isadministered by the oral parenteral route in the form of a tablet,capsule, or liquid, twice daily (bid). Maximal concentrations of potatopolysaccharide are initially administered bid over the course of onemonth. Positive outcome measures include: (1) restoration of normalfasting blood glucose, (2) significant weight loss and lowering of BMI,(3) augmentation of serum LDL/HDL ratio, (4) lowering serum triglycerideconcentration, (5) lowering serum concentration of free fatty acids, (6)lowering systolic and diastolic blood pressure, (7) enhancement ofinsulin sensitivity, and (8) lowering insulin requirement in Type IIdiabetes patients.

Example 8 Using a Potato Polysaccharide Preparation to Treat aPolycystic Ovary Syndrome

Once a polycystic ovary syndrome (POS) patient is identified, thepatient is treated as follows. Potato polysaccharide is formulated inthe presence of alpha lipoic acid or alpha tocopherol or both.Formulated potato polysaccharide is added to 90% by weight inert bindermaterial and is administered by the oral parenteral route in the form ofa tablet, capsule, or liquid, twice daily (bid). Maximal concentrationsof potato polysaccharide are initially administered bid over the courseof one month. Positive outcome measures include: (1) restoration ofnormal reproductive function, (2) restoration of normal ovarian folliclematuration, (3) restoration of normal fasting blood glucose levels, (4)significant weight loss and lowering of BMI, (5) augmentation of serumLDL/HDL ratio, (6) lowering serum triglyceride concentration, (7)lowering serum concentration of free fatty acids, (8) lowering systolicand diastolic blood pressure, (9) enhancement of insulin sensitivity,and (10) lowering insulin requirement in comorbid POS patients with typeII diabetes.

Example 9 Maintaining and Restoring Insulin Sensitivity and GlucoseHomeostasis in Living Mammals In Vivo Animal Model

The Zucker Diabetic Fatty (ZDF) rat model was used (Carley and Severson,Biochim. Biophys. Acta, 1734:112-26 (2005)). Positive results in the ZDFrat model can indicate a potential for positive treatment outcomes inhuman Type II diabetics. In particular, circulating plasma triglycerideconcentrations, circulating plasma glucose concentrations, abdominalfat, water utilization, urine secretion, and organ weights were examinedin cohorts of ZRF rats treated with a potato polysaccharide preparationor with vehicle.

Dosing and Grouping

Two types of rats were used for the study (ZDF/ZDF rats (n=20) andheterozygous lean rats (n=20)). The rats within the groups were thenchosen at random and divided into groups of 10. Group 1 included the ZDFvehicle fed rats, group 2 included the ZDF potato polysaccharide fedrats, group 3 included the lean vehicle fed rats, and group 4 includedthe lean potato polysaccharide fed rats. The vehicle was distilledwater, and the potato polysaccharide was given daily each morning viaoral gavage at a dosage of 0.05 mg per animal. The dose was usuallygiven in 1 mL of water. Rats were caged in groups and maintained in 12hour light/12 hour dark (7 am to 7 pm). The study lasted for 28 days.

Data Collection

Body weights were recorded weekly. Whole blood, serum, and plasma werecollected at day 0 for baseline analysis. Plasma and serum was collectedfrom fasting rats at day 14. Water consumption was monitored starting atday 24 and continued until termination. Urine collection for measurementof volume and protein content was on day 27. Whole blood, serum, andplasma were collected at day 28 (termination). Fasted blood glucose wasmeasured at day 28, and liver and abdominal fat were collected and snapfrozen in liquid nitrogen.

Total cholesterol (HDL, LDL, and triglycerides) and serum glucose weremeasured at days 0, 14, and 28. Serum creatinine was measured attermination. Whole blood was preserved in PAX RNA blood tubes forpossible gene expression analysis. Abdominal fat, liver, and kidneyswere weighed and used in calculating organ to body mass ratios. Plasmacollected was stored from days 0, 14, and 28 for possible futureanalysis.

Experimental Animals

Twenty-two 7-week old, male Zucker Diabetic Fatty rats (ZDF, Code: 370)and twenty-two 7-8 week old, male ZDF Lean rats (Code: 371) werepurchased from Charles Rivers Laboratories (Wilmington, Mass.). Thestudy animals were allowed an acclimation period of 4 days prior tobaseline blood collections, at which time two extra animals from eachstrain were dropped from the study based on baseline body weight. Therats were housed two rats per cage and maintained in the Innovive cagingsystem (San Diego, Calif.) upon arrival. Cages were monitored daily toensure the Innovive system maintained 80 air changes per hour andpositive pressure. Rat rooms were maintained at temperatures of 66-75°F. and a relative humidity between 30 percent and 70 percent. The roomswere lit by artificial light for 12 hours each day (7:00 am to 7:00 pm).Animals had free access to water and Purina 5008 rodent food(Waldschimdt's, Madison, Wis.) for the duration of the study exceptduring fasted experiments.

Drug Formulation

A potato polysaccharide preparation for animal testing was prepared asfollows. Ten gram portions of raw potato material were homogenized witha Polytron homogenizer in ten volumes of distilled water and maintainedat room temperature for 1 hour with occasional shaking. The raw potatohomogenate was subsequently centrifuged at 4000 g for 10 minute in orderto remove insoluble material. The resulting supernatant was purified bySolid Phase Extraction utilizing a Sep-Pak Plus C-18 cartridge.Semipurified polysaccharide material contained in 10 percentacetonitrile and 0.05% trifluoroacetic acid was dried and purified tohomogeneity by reverse phase HPLC.

The eluted 3.5 minute HPLC fraction containing pure potatopolysaccharide preparation was dried and used in animal testing.

The purified potato polysaccharide preparation (10 mL stock solution at5 mg/mL concentration) was stored at 4° C. The vehicle for the study wassterile water (Catalog number 002488, Butler Schein). Each week, thestock solution was diluted 1:100 in sterile water (0.05 mg/mL) anddispensed into daily aliquots. All vehicle and drug solutions werestored at 4° C. and administered at room temperature daily by oralgavage (PO) in a volume of 1 mL/animal (0.15 mg/kg dose based onestimated body weight of 350 g).

Body Weights

Animals were weighed weekly with a calibrated digital balance to monitoranimal health. Body weights were taken in a fed state, except for theterminal body weight measurement.

Blood Collection

Blood was collected on Day 0 for baseline, Day 14 for Week 2, and Day 28during termination for Week 4. Animals were fasted for 11.5 hours (10:00pm-9:30 am) prior to each blood collection, and if applicable, dosed 1hour prior to the blood collection. Whole blood was collected into bloodcollection tubes for baseline pooled blood analysis (1.0 mL of bloodfrom each animal) and terminal blood analysis (2.5 mL of blood from eachanimal). For Baseline and Days 14 and 28, 850 μL of whole blood wascollected into pre-chilled K2EDTA tubes with DPP4i (1:100 P8340, SigmaAldrich) added and processed to plasma. For Baseline and Days 14 and 28,250 μL whole blood was collected into a SST tube and processed to serum.

Blood Analyses

Whole blood collected into blood tubes was frozen at −20° C. and shippedon ice packs for analyses. Plasma with DPP4i added were frozen at −20°C. and shipped on dry ice for analyses. Serum was frozen at −20° C. andshipped for analysis. Baseline and Day 14 sera were analyzed for thestandard lipid panel (cholesterol, triglycerides, HDL, and LDL) as wellas glucose. Terminal serum samples were analyzed for the standard lipidpanel, glucose, and creatinine content.

Water Consumption

Beginning on Day 23, water consumption monitoring began and wascontinued for the remainder of the study. The difference in water weight(beginning weight of water in grams minus the end weight of water ingrams) was divided by the number of animals per cage to determine theaverage amount of water in grams consumed per animal per day. Wateradded was accounted for in the measurements, and calculations wereconverted to mL/animal/day. On Day 26, animals were placed intoindividual metabolic cages; therefore, water consumption was monitoredper animal instead of per cage.

Urine Collection

Urine was collected at room temperature for 24 hours from Day 26 to Day27. Animals had free access to food and water throughout the procedure.Urine volumes were measured, and urine protein and creatinine wereanalyzed.

Fasted Glucose

Fasted blood glucose was measured at 9:30 am on Day 28, about 1 hourpost-dose with 11.5 hours of fasting. Blood glucose was measured with aBayer Contour glucometer. Termination immediately followed the bloodglucose measurements.

Necropsy

All animals were euthanized by isoflurane overdose and thoracotomyfollowing the collection of fasted blood glucose data on Day 28 of thestudy. Blood was collected via descending vena cava. Liver and abdominalfat were collected and weighed, and a portion of the left lateral liverlobe and abdominal fat were placed into individual histology cassettesand snap frozen in liquid nitrogen. General pathological observationswere recorded.

Study Design

Animals were recruited into treatment groups based on body weightscollected on Day-1. Animals were fasted for 11.5 hours (10:00 pm-9:30am) prior to collection of blood on Day 0 for baseline parameteranalyses. Each animal was anesthetized using isoflurane inhalantanesthetic with subsequent retro-orbital blood collection technique,followed by subcutaneous fluid replacement. Study animals receivedvehicle (sterile water) or a potato polysaccharide via oral gavagebeginning on Day 1 and for the duration of the experiment. Animals wereadministered 1.0 mL of a 0.05 mg/mL solution to achieve a target dose of0.15 mg/kg/day.

At the end of Week 2, animals were fasted and dosed prior to collectionof blood on Day 14 for mid-study parameter analyses. Each animal wasanesthetized using isoflurane inhalant anesthetic with subsequentretro-orbital blood collection technique. Water consumption monitoringbegan on Day 23 and continued for the duration of the study. On Day 26,study animals were placed into individual metabolic cages for a 24-hourcollection of urinary output. Urine volume was measured, and two clean,processed aliquots were retained for analysis.

At the end of Week 4, animals were fasted and dosed prior to measurementof blood glucose on Day 28. Fasted blood glucose was measured via tailclip blood collection, and termination began directly thereafter.Animals were euthanized using isoflurane inhalant anesthetic followedwith a thoracotomy. Blood was collected via the descending vena cava anddistributed into the appropriate tubes. The liver and abdominal fat werecollected and weighed, and portions snap frozen in liquid nitrogen. Thestudy design and treatments in the groups for the rats are presented inFIG. 37 and Table 11.

TABLE 11 Treatment Groups. Group 1: Fa/Fa Vehicle (Sterile Water), n =10 Group 2: Fa/Fa potato polysaccharide 0.05 mg/day, n = 10 Group 3:Lean +/? Vehicle (Sterile Water), n = 10 Group 4: Lean +/? potatopolysaccharide 0.05 mg/day, n = 10 +/? represents the ZDF lean rats thatare heterozygotic with a normal leptin receptor allele and that displayno abnormal metabolic symptoms.

Statistical Analysis

Data were reported in mean+SEM. Statistical analysis was performed usingthe Prism 5.0d program by GraphPad Software. Analysis of variation forbody weight, lipid panel parameters (cholesterol, triglycerides, HDL,and LDL), serum glucose, and water consumption were performed through atwo-way ANOVA. Bonferroni post-tests were used to compare replicatemeans by row. Analysis of variation for blood glucose, urine parameters(urine volume, proteinuria, and creatinine clearance), liver-to-bodyweight ratio, and abdominal fat-to-body weight ratio were performedthrough a one-way ANOVA with a Bonferroni post-test to compare all pairsof columns. Significance was determined when the p-value was less thanan alpha of 0.05 with a confidence interval of 95%. Outliers werescreened by testing the group's mean versus the standard error of themean (SEM) for said time point. If the relationship of SEM to mean wasin excess of 10%, then the data points of that group at that time pointwere carried through an outlier test. Data points outside a z-scorevariation of 3.0 were listed as outliers and not included in the mean orSEM for the group. In Group 1 for Day 6 body weight, one animal's valuewas considered an outlier and was removed from the graphs andstatistical analysis.

Results

Mean body weight between the four groups did not change (FIG. 38).Comparing groups 1 and 2, the rats treated with a potato polysaccharidepreparation exhibited a significant drop in triglyceride levels at day14 (P<0.05; FIG. 39). On day 0, mean LDL was lower in Group 4 ascompared to Group 3 (FIG. 40). Mean serum glucose was statisticallylower on day 28 for rats of Group 2 treated with the potatopolysaccharide preparation (FIG. 41). Rats of Group 2, which weretreated with a potato polysaccharide preparation, exhibited astatistically significant reduction in water consumption and urineproduction (FIGS. 42 and 43) as compared to the rats of Group 1. Rats ofGroup 2 exhibited mean fasted glucose levels that were statisticallylower than the levels observed for rats of Group 1 (FIG. 44). Abdominalfat in the potato polysaccharide preparation treated group wasstatistically elevated (FIG. 45). In addition, the kidney weight to bodyweight ratio was lower for the rats of Group 2 as compared to those forthe rats of Group 1 (FIG. 46).

These results demonstrate that administration of a potato polysaccharidepreparation can maintain the metabolic integrity of adipocytes during acritical developmental period of insulin desensitivity observed invehicle-treated ZDF controls. In the vehicle-treated cohort, adevelopmental period highlighted by markedly increased plasmatriglyceride concentrations is functionally linked to temporaldevelopment of insulin desensitization and diabetic levels of plasmaglucose. In the cohort treated with a potato polysaccharide preparation,a statistically significant reduction of plasma triglycerideconcentrations was observed at the 14 day time point, which iscritically linked to significantly lower levels of fasting andnon-fasting “true” glucose. Lower levels of plasma glucose wereassociated with significantly reduced water intake and urine output,indicating a marked inhibition of the development of multiple type IIdiabetic symptoms.

These positive outcomes are directly translatable to inhibition of typeII diabetes development in humans. Interestingly, levels of true glucosein vehicle-treated ZDF controls were lower than those observed intreated ZDF rats at early time points. This was consistent with temporaldevelopment of insulin insensitivity in humans via presentation ofprediabetic lowered plasma glucose levels. Administration of a potatopolysaccharide preparation was observed to inhibit temporal developmentof prediabetic lowered levels of plasma glucose. In effect,administration of a potato polysaccharide preparation maintained normallevels of plasma glucose via maintenance of insulin sensitivity.Maintenance of normal levels of plasma glucose was statistically linkedto diminished circulating plasma triglycerides at the 14 day time point,which was functionally linked to higher levels of abdominal fat intreated animals that were normally observed in obese non-diabetichumans. In summary, administration of a potato polysaccharidepreparation as described herein maintained metabolic integrity ofabdominal fat storage that is linked to temporal development of insulininsensitivity. This also indicates that a potato polysaccharidepreparation can be used to stabilize metabolic processes in obese humanpopulations, thereby permitting programmed dietary regimens to combatobesity disorders effectively.

Example 10 Use of Potato Polysaccharide Preparations to Treat FattyLiver Diseases

To assess the ability of potato polysaccharide preparations to treatfatty liver diseases, the livers from the rats of the four groups ofExample 9 were collected, weighed, and examined as described in thisExample.

DNA Microarray

Total RNA extracted from liver samples was isolated and purified usingthe RNeasy mini kit (Qiagen, Valencia, Calif.). In particular, 100 mg oftissue was resuspended in 1.8 mL of RLT lysis buffer (Qiagen) andhomogenized with a polytron homogenizer for 30 seconds. The samples werethen processed according to the manufacturer's instructions (Qiagen,Valencia, Calif.). In the final step, the RNA was eluted with 50 μL ofRNase-free water by centrifugation for 1 minute at 13,000 g. The RNA wasanalyzed on a model 2100 bioanalyzer (Agilent, Santa Clara, Calif.)using a total RNA nanochip according to the manufacturer's protocol.

DNA microarray analyses were performed using a system provided byAgilent. Arrays included four arrays per chip (Agilent Rat geneexpression 4X44K version 3 chips). Total RNA was reverse transcribed(700 ng) using T7 primers, labeled, and transcribed using Cyanine-3 dye.Each array was hybridized with 2 μg of labeled cRNA at 65° C. for 18hours. Arrays were scanned using an Agilent array scanner.

Results

Oral administration of the potato polysaccharide preparation over a timecourse of 28 days produced a statistically significant reduction (about40%) in the liver weight to body weight ratios in Zucker ZDF rats, ascompared to control Zucker ZDF rats receiving vehicle (p=0.01, N=9).

In addition, daily oral administration of the potato polysaccharidepreparation resulted in a coordinated enhancement of gene expression inliver tissue that is functionally linked to enhanced protein and nucleicacid biosynthesis (Table 12).

TABLE 12 Enhanced expression of genes driving mitochondrial biogenesislinked to enhanced protein and nucleic acid biosynthesis. Gene FoldSymbol Gene Name Change P value Slc25a33 solute carrier family 25(pyrimidine 3.6 0.00005 nucleotide carrier), member 33 Tomm40translocase of outer mitochondrial 2.4 0.0005 membrane 40 homolog(yeast) Mrpl3 mitochondrial ribosomal protein L3 2.4 0.000008 Mrps18bmitochondrial ribosomal protein 1.9 0.002 S18B Mrps9 mitochondrialribosomal protein S9 1.8 0.001 Fars2 phenylalanyl-tRNA synthetase 2, 1.80.001 mitochondrial Mrpl15 mitochondrial ribosomal protein L15 1.7 0.004Mrps23 mitochondrial ribosomal protein S23 1.6 0.0003 Mrps2mitochondrial ribosomal protein S2 1.6 0.003 Mrpl17 mitochondrialribosomal protein L17 1.5 0.0001 TFAM Transcription factor A 1.5 0.05

Daily oral administration of the potato polysaccharide preparation alsoresulted in a coordinated enhancement of gene expression in liver tissuethat is functionally linked to enhanced TCA cycle activity and ATPproduction (Table 13).

TABLE 13 Enhanced expression of genes driving mitochondrial energyproduction. Gene Fold Symbol Gene Name Change P value Prodh prolinedehydrogenase (oxidase) 1 2.9 0.003 Slc25a1 solute carrier family 25(mitochondrial 2.3 0.00004 carrier, citrate transporter), member 1 Hmgcl3-hydroxymethyl-3-methylglutaryl- 2.2 0.0004 CoA lyase Cps1carbamoyl-phosphate synthetase 1 2.0 0.0001 Aldh4a1 aldehydedehydrogenase 4 family, 1.9 0.0003 member A1 Mdh2 malate dehydrogenase2, NAD 1.9 0.0002 (mitochondrial) Atp5b ATP synthase, H+ transporting,1.8 0.0002 mitochondrial F1 complex, beta polypeptide Slc25a22 solutecarrier family 25 (mitochondrial 1.6 0.0007 carrier, glutamate), member22 Slc25a19 solute carrier family 25 (mitochondrial 1.6 0.00009 thiaminepyrophosphate carrier), member 19 Uqcrc2 ubiquinol cytochrome creductase core 1.6 0.0001 protein 2 Abcf2 ATP-binding cassette,subfamily F 1.6 0.004 (GCN20), member 2

Daily oral administration of the potato polysaccharide preparationresulted in differential expression of genes functionally involved inlipogenesis, triglyceride assembly, and mitochondrial lipolysis (Table14).

TABLE 14 Differential expression of genes involved in lipogenesis,triglyceride assembly, and mitochondrial lipolysis. Gene Symbol GeneName Fold Change P value Acbd4 acyl-CoA binding domain containing 3.00.00003 4 Fads1 fatty acid desaturase 1 1.9 0.003 Gnpatglyceronephosphate O-acyltransferase 1.6 0.002 Lypla1 lysophospholipaseI 1.5 0.001 Cpt2 Carnitine palmitoyltransferase 1.2 0.04 Pck2phosphoenolpyruvate carboxykinase 2 −1.4 0.003 (mitochondrial) Agpat41-acylglycerol-3-phosphate O- −1.8 0.001 acyltransferase 4(lysophosphatidic acid acyltransferase, delta Acaca acetyl-CoAcarboxylase alpha −2.3 0.00007

Daily oral administration of the potato polysaccharide preparation didnot result in any significant change in the expression of three hepaticreference or housekeeping genes (Congiu et al., Liver Int., 31:386-90(2011); Table 15).

TABLE 15 Expression of hepatic reference or housekeeping genes. Meansignal Gene Symbol Gene Name difference Gapdh glucuronidase, beta 0.1Hprt hypoxanthine 0.06 phosphoribosyltransferase 1 Srsf4serine/arginine-rich splicing factor 4 0.004

Real-time PCR analysis of TFAM expression was performed to validate theDNA microarray data sets. After rats were given the potatopolysaccharide preparation for 28 days, real-time PCR was performed tomeasure changes in TFAM gene expression in ZDF rat livers. GAPDH wasused as a reference gene. The real-time PCR master mix included 25 μL 2×universal master mix, 2.5 μL 20× detector set (with the primer andprobe), and 21.5 μL of water. PCR was performed in an Applied Biosystems7500 sequence detection system. The thermocycler conditions includeddenaturation at 95° C. for 15 seconds and annealing/extension at 60° C.for 60 seconds. Forty cycles of PCR were preceded by 95° C. for 10minutes. Reactions were performed in triplicate. The relative quantitiesof TFAM were determined using the formula 2-ΔΔCt using the AppliedBiosystems 7500 software. There was a 3.4±0.5 fold change increaserelative to the untreated rats (FIGS. 48 and 49).

Taken together, these results demonstrate that potato polysaccharidepreparations can be used as anti-steatotic agents to treat fatty liverdiseases.

Other Embodiments

It is to be understood that while the invention has been described inconjunction with the detailed description thereof, the foregoingdescription is intended to illustrate and not limit the scope of theinvention, which is defined by the scope of the appended claims. Otheraspects, advantages, and modifications are within the scope of thefollowing claims.

What is claimed is:
 1. A method for treating diabetes, wherein saidmethod comprises: (a) identifying a mammal with diabetes, and (b)administering to said mammal a composition comprising a potatopolysaccharide preparation obtained from raw potatoes, wherein theseverity of a symptom of said diabetes is reduced.